We are live on
!
Find out more
DTC
Deep Track Capital Portfolio holdings
AUM
$6.87B
1-Year Est. Return
205.24%
This Fund
S&P 500
This Quarter
Est. Return
+8.81%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$6.12B
AUM Growth
+$515M
(+9.2%)
Cap. Flow
+$653M
Cap. Flow
% of AUM
10.66%
Top 10 Holdings %
Top 10 Hldgs %
53.58%
Holding
69
New
14
Increased
25
Reduced
14
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALMS
Alumis Inc
ALMS
|
+$169M |
| 2 |
NUVL
Nuvalent
NUVL
|
+$140M |
| 3 |
Ocular Therapeutix
OCUL
|
+$111M |
| 4 |
Genmab
GMAB
|
+$110M |
| 5 |
Vera Therapeutics
VERA
|
+$55.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DVAX
Dynavax Technologies
DVAX
|
+$242M |
| 2 |
Cytokinetics
CYTK
|
+$125M |
| 3 |
APLS
Apellis Pharmaceuticals
APLS
|
+$69.3M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$67.1M |
| 5 |
MAZE
Maze Therapeutics
MAZE
|
+$33.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 79.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Kura Oncology
KURA
$966M
| $21.5M | 0.35% |
+2,643,542
| New | +$22.7M |
|
52
Century Therapeutics
IPSC
$348M
| $21.4M | 0.35% |
+9,487,745
| New | +$19.9M |
|
53
Beam Therapeutics
BEAM
$2.76B
| $19.6M | 0.32% |
+820,765
| New | +$22.8M |
|
54
Context Therapeutics
CNTX
$48M
| $19.4M | 0.32% |
7,419,355
| – | – |
|
55
Personalis
PSNL
$1.5B
| $19.1M | 0.31% |
+3,000,000
| New | +$25.3M |
|
56
Janux Therapeutics
JANX
$986M
| $16.5M | 0.27% |
1,187,290
+1,097,701
| +1,225% | +$15.1M |
|
57
ProMIS Neurosciences
PMN
$130M
| $10.6M | 0.17% |
+835,655
| New | +$12.5M |
|
|
CBIO
58
Crescent Biopharma
CBIO
$637M
| $8.33M | 0.14% |
453,686
| – | – |
|
|
IVA
59
Inventiva
IVA
$1.09B
| $6.78M | 0.11% |
1,222,453
+732,453
| +149% | +$4.47M |
|
60
Larimar Therapeutics
LRMR
$453M
| $6.75M | 0.11% |
+1,500,000
| New | +$6M |
|
|
HELP
61
Cybin Inc
HELP
$743M
| $6.3M | 0.1% |
1,313,137
-541,118
| -29% | -$3.5M |
|
|
BLLN
62
BillionToOne Inc
BLLN
$4.4B
| $3.95M | 0.06% |
50,000
| – | – |
|
63
Aligos Therapeutics
ALGS
$43M
| $3.3M | 0.05% |
444,110
| – | – |
|
|
ANL
64
Adlai Nortye
ANL
$853M
| – | – |
-34,852
| Closed | -$49.5K |
|
65
CALL
Biohaven
BHVN
$2.21B
| – | – |
-500,000
| Closed | -$5.64M |
|
|
DVAX
66
DELISTED
Dynavax Technologies
DVAX
| – | – |
-15,726,349
| Closed | -$242M |
|
67
Monopar Therapeutics
MNPR
$759M
| – | – |
-95,408
| Closed | -$6.23M |
|
|
RAPT
68
DELISTED
RAPT Therapeutics
RAPT
| – | – |
-110,448
| Closed | -$3.74M |
|
69
Xenon Pharmaceuticals
XENE
$6.03B
| – | – |
-366,435
| Closed | -$16.4M |
|
Similar funds
PFS
EWM
NP
NPT
RCWMU
CA
CI
TCM
Deep Track Capital's Q1 2026 Portfolio in Review
As of Q1 2026, Deep Track Capital held 69 positions worth $6.12B, up 9.2% from $5.61B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Deep Track Capital deployed $653M of net new capital in Q1 2026, opening 14 new positions and adding to 25 existing holdings. Its largest new stake was Alumis Inc: 6,772,595 shares worth $149M.
By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 78% a quarter earlier.
On the sell side, the largest reduction was Cytokinetics, an estimated $125M trimmed.
- Deep Track Capital's largest Q1 2026 buy was Alumis Inc: 6,772,595 shares worth $149M.
- Deep Track Capital added most to Ocular Therapeutix in Q1 2026, an estimated $111M increase.
- Deep Track Capital's biggest Q1 2026 reduction was Cytokinetics, cutting an estimated $125M.
- Deep Track Capital fully exited Dynavax Technologies in Q1 2026, selling an estimated $242M.
- Deep Track Capital's ten largest holdings make up 54% of its $6.12B portfolio in Q1 2026.
- Deep Track Capital opened 14 new positions and closed 6 in Q1 2026.
- Deep Track Capital's portfolio value rose 9.2% quarter-over-quarter to $6.12B.
Based on Deep Track Capital's 13F filing for Q1 2026, filed 15 May 2026.